First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.
The company posted quarterly losses of 95 cents per share, versus losses of $1.47 per share in the year-ago period.
“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases,” said Daniel Faga, president and chief executive officer.
First Tracks shares rose 0.1% to $46.16 in pre-market trading
These analysts made changes to their price targets on First Tracks following earnings announcement.
